KR20040030042A - 안구 질환을 치료하기 위한 투불린 결합제 투여 조성물 및방법 - Google Patents

안구 질환을 치료하기 위한 투불린 결합제 투여 조성물 및방법 Download PDF

Info

Publication number
KR20040030042A
KR20040030042A KR10-2004-7000464A KR20047000464A KR20040030042A KR 20040030042 A KR20040030042 A KR 20040030042A KR 20047000464 A KR20047000464 A KR 20047000464A KR 20040030042 A KR20040030042 A KR 20040030042A
Authority
KR
South Korea
Prior art keywords
eye
ocular
effective amount
combretastatin
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR10-2004-7000464A
Other languages
English (en)
Korean (ko)
Inventor
셰리스데빗
우드마크
Original Assignee
옥시젠 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 옥시젠 인코포레이티드 filed Critical 옥시젠 인코포레이티드
Publication of KR20040030042A publication Critical patent/KR20040030042A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
KR10-2004-7000464A 2001-07-13 2002-07-15 안구 질환을 치료하기 위한 투불린 결합제 투여 조성물 및방법 Ceased KR20040030042A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US38622701P 2001-07-13 2001-07-13
US60/386,227 2001-07-13
US37755602P 2002-05-03 2002-05-03
US37784502P 2002-05-03 2002-05-03
US37784702P 2002-05-03 2002-05-03
US60/377,556 2002-05-03
US60/377,845 2002-05-03
US60/377,847 2002-05-03
PCT/US2002/022449 WO2003006002A1 (en) 2001-07-13 2002-07-15 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases

Publications (1)

Publication Number Publication Date
KR20040030042A true KR20040030042A (ko) 2004-04-08

Family

ID=32034390

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7000464A Ceased KR20040030042A (ko) 2001-07-13 2002-07-15 안구 질환을 치료하기 위한 투불린 결합제 투여 조성물 및방법

Country Status (8)

Country Link
EP (1) EP1406600A4 (https=)
JP (2) JP2004536847A (https=)
KR (1) KR20040030042A (https=)
CN (1) CN1527704B (https=)
CA (1) CA2453442C (https=)
NZ (1) NZ575466A (https=)
WO (1) WO2003006002A1 (https=)
ZA (1) ZA200400210B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229960A1 (en) * 2001-07-13 2004-11-18 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
JP4005048B2 (ja) * 2003-04-09 2007-11-07 日信工業株式会社 炭素繊維複合材料およびその製造方法
JP2012532113A (ja) * 2009-07-02 2012-12-13 オキシジーン， インコーポレイテッド 後嚢混濁を予防するためのコンブレタスタチン
CN102596197A (zh) 2009-08-27 2012-07-18 生物学特性有限公司 用于治疗增生性疾病的联合疗法
JP2013502440A (ja) * 2009-08-27 2013-01-24 バイオノミックス リミテッド 黄斑変性の治療
PT2880089E (pt) * 2012-08-02 2016-06-17 Amril Ag Borracha natural que contém nanocarbono
CN113520995B (zh) * 2021-08-16 2023-03-10 海南鑫开源医药科技有限公司 一种离子敏感型眼用原位凝胶、其制备方法及应用
CN113577020B (zh) * 2021-08-16 2022-09-23 海南鑫开源医药科技有限公司 一种玻璃体腔内注射剂、其制备方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338645C (en) * 1987-01-06 1996-10-15 George R. Pettit Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins"
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
JP2002500227A (ja) * 1998-01-09 2002-01-08 アリゾナ ボード オブ リーゼンツ コンブレタスタチンａ−４プロドラッグとそのトランス異性体
GB9903404D0 (en) * 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
WO2000048606A1 (en) * 1999-02-18 2000-08-24 Oxigene, Inc. Compositions and methods for use in targeting vascular destruction
US6670344B2 (en) * 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts

Also Published As

Publication number Publication date
WO2003006002A1 (en) 2003-01-23
JP2004536847A (ja) 2004-12-09
CA2453442A1 (en) 2003-01-23
WO2003006002A8 (en) 2004-05-27
JP2009132738A (ja) 2009-06-18
CA2453442C (en) 2011-02-01
NZ575466A (en) 2011-01-28
WO2003006002A9 (en) 2004-07-22
ZA200400210B (en) 2005-06-29
EP1406600A4 (en) 2007-06-06
CN1527704A (zh) 2004-09-08
CN1527704B (zh) 2011-05-18
EP1406600A1 (en) 2004-04-14

Similar Documents

Publication Publication Date Title
US20030181531A1 (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
TWI260327B (en) Pharmaceutical compositions for treating ocular neovascular diseases
JP2009132738A (ja) 眼の疾患の処置のためのチューブリン結合薬剤を投与するための組成物および方法
RU2359693C2 (ru) Композиции и способы введения средств, связывающих тубулин, для лечения глазных заболеваний
Reese Tumors of the eye and adnexa
US20100190734A1 (en) Method of treating dry eye disease with azithromycin
US20210038668A1 (en) Traditional chinese medicine composition for preventing and/or treating ischemic reperfusion injury
CN110869045B (zh) 包含i型胶原及色素上皮衍生因子肽作为有效成分的预防或治疗新生血管性疾病的药物组合物
US20050054586A1 (en) Treatment of ophthalmic disorders
RU2354398C2 (ru) Композиции и способы введения средств, связывающих тубулин, для лечения глазных заболеваний
AU2008202468B2 (en) Compositions and Methods of Administering Tubulin Binding Agents for the Treatment of Ocular Diseases
CN116650461A (zh) 咖啡酸苯乙酯滴及其眼液在制备治疗糖尿病视网膜病变药物中的应用
CN109789115A (zh) 用于治疗眼疾的方法
AU2002322494A1 (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
JP2005521681A (ja) 尿素および尿素誘導体を使用した眼科疾患の治療方法
RU2359648C2 (ru) Способ лечения меланомы хориоидеи
EP4338798A1 (en) Pharmaceutical preparation containing genistein for use in the prevention or treatment of glaucoma and/or ocular hypertension
JP2004331502A (ja) 視神経細胞保護剤
RU2303965C2 (ru) Способ лечения внутриглазных новообразований большого размера
Abdel-Ghaffar et al. Potential prophylactic effect of Naringenin loaded liposome eye drops on streptozotocin-induced diabetic cataract in rats
Kozera et al. Neuroprotection to counteract glaucomatous degeneration of retina; the use of citicoline
WO2025140240A1 (zh) 一种用于治疗和/或预防角膜损伤的药物组合物和方法
WO2023176720A1 (ja) 網膜血管拡張剤及び医薬組成物
RU2315585C1 (ru) Способ хирургического лечения глаукомы
WO2000076454A2 (en) Therapeutic compositions for ophthalmic use and therapeutic compositions for brain central lesions

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20040112

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20070716

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20080625

Patent event code: PE09021S01D

AMND Amendment
E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20090429

Patent event code: PE09021S02D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20100128

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20090429

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20080625

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20100427

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20100128

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20110526

Appeal identifier: 2010101003096

Request date: 20100427

AMND Amendment
PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20100526

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20100427

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20090929

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20081224

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20070716

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial

Comment text: Report of Result of Re-examination before a Trial

Patent event code: PB06011S01D

Patent event date: 20100610

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20100427

Effective date: 20110526

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20110526

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20100427

Decision date: 20110526

Appeal identifier: 2010101003096